Qimanguli Saiding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qimanguli Saiding has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Wei Tao
Department of Pharmacology Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore
6 shared publications - Wenguo Cui
Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Department of Orthopaedics Shanghai Institute of Traumatology and Orthopaedics Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
3 shared publications Chuao Yu
Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, School of Pharmacy, Hangzhou Normal University
2 shared publications- Fan Xiao
Department of Respiratory and Critical Care Medicine Sir Run Run Shaw Hospital Zhejiang University School of Medicine Hangzhou Zhejiang P. R. China
2 shared publications Jianhua Zou
Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, School of Pharmacy, Hangzhou Normal University
2 shared publicationsMeng Li
Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, School of Pharmacy, Hangzhou Normal University
2 shared publications
Latest Publications
- 6 March 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (10) , 11370-11381
Sprayable Lactococcus lactis -Nanocatalyst Gel for Postsurgical Immunomodulation in Preclinical Oral Squamous Cell Carcinoma
Oral squamous cell carcinoma (OSCC) is one of the most prevalent and aggressive head and neck cancers. Emerging evidence shows that distinct microbiomes coexist with tumor and immune cells in the tumor microenvironment (TME), shaping tumor progression and antitumor immunity. Harnessing probiotic-based immune modulation therefore represents a promising strategy to improve postoperative outcomes. Here, we develop a dual-channel sprayable Lactococcus lactis probiotic-nanocatalyst gel (L. lactis@Co4N/C@Gel) to potentiate postoperative immune reconstruction in OSCC. L. lactis can activate antitumor responses through Toll-like and NOD-like receptor pathways. However, its therapeutic benefit is constrained by lactate overproduction, which promotes tumor aggressiveness, immunosuppression, and therapy resistance. The incorporated Co4N/C nanoparticles efficiently scavenge L. lactis-derived lactate, thereby amplifying downstream immune activation. Benefiting from the thixotropic properties of calcium alginate, a sodium alginate solution containing L. lactis and CaCl2 solution containing Co4N/C nanoparticles can be cosprayed to achieve uniform wound coverage and rapid in situ gelation. In an orthotopic OSCC mouse model, L.lactis@Co4N/C@Gel effectively reconstructs postoperative antitumor immunity and markedly suppresses tumor recurrence. These findings highlight a microbiome-nanocatalyst synergistic strategy for improving postoperative immunotherapy in OSCC.
- 6 March 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (10) , 11370-11381
Sprayable Lactococcus lactis -Nanocatalyst Gel for Postsurgical Immunomodulation in Preclinical Oral Squamous Cell Carcinoma
Oral squamous cell carcinoma (OSCC) is one of the most prevalent and aggressive head and neck cancers. Emerging evidence shows that distinct microbiomes coexist with tumor and immune cells in the tumor microenvironment (TME), shaping tumor progression and antitumor immunity. Harnessing probiotic-based immune modulation therefore represents a promising strategy to improve postoperative outcomes. Here, we develop a dual-channel sprayable Lactococcus lactis probiotic-nanocatalyst gel (L. lactis@Co4N/C@Gel) to potentiate postoperative immune reconstruction in OSCC. L. lactis can activate antitumor responses through Toll-like and NOD-like receptor pathways. However, its therapeutic benefit is constrained by lactate overproduction, which promotes tumor aggressiveness, immunosuppression, and therapy resistance. The incorporated Co4N/C nanoparticles efficiently scavenge L. lactis-derived lactate, thereby amplifying downstream immune activation. Benefiting from the thixotropic properties of calcium alginate, a sodium alginate solution containing L. lactis and CaCl2 solution containing Co4N/C nanoparticles can be cosprayed to achieve uniform wound coverage and rapid in situ gelation. In an orthotopic OSCC mouse model, L.lactis@Co4N/C@Gel effectively reconstructs postoperative antitumor immunity and markedly suppresses tumor recurrence. These findings highlight a microbiome-nanocatalyst synergistic strategy for improving postoperative immunotherapy in OSCC.
- 16 February 2026
- Published by American Chemical Society (ACS) in Accounts of Chemical Research
- Vol. 59 (5) , 762-775
Lipid–Polymer Hybrid Nanoparticles (LPHNPs) for RNA Delivery
ConspectusRNA-based therapeutics are now revolutionizing modern medicine, with examples like COVID-19 mRNA vaccines and the siRNA drug Leqvio, validating their potential in infectious diseases and chronic diseases. However, the broad clinical translation of RNA therapeutics remains critically dependent on the development of safe and effective delivery systems that are capable of overcoming physiological barriers and achieving precise spatiotemporal upregulation or downregulation of target proteins. Lipid nanoparticles (LNPs) have attracted significant attention due to their clinical success, yet they still struggle to overcome context-specific delivery barriers, such as poor stability in blood or gastrointestinal fluids, lack of disease-microenvironment responsiveness, and insufficient cell-type targeting, which hinder the full implementation of RNA therapeutics across a broad spectrum of diseases. To tackle the unmet needs in RNA-based therapeutics, developing new types of delivery platforms with different nanoparticle structures is therefore highly attractive and needed.Over the past decade, our group has focused on developing novel lipid-polymer hybrid nanoparticles (LPHNPs) for the delivery of RNA therapeutics across diverse biomedical applications. By incorporating biodegradable polymers with tailored properties, for example, poly(lactic-co-glycolic acid) (PLGA) for structural stability, hyaluronic acid (HA) for CD44-mediated targeted delivery, and l-cysteine-based poly(disulfide amide) (Cys-PDSA) for redox-responsive release in the tumor microenvironment, these LPHNPs exhibit highly tunable architectures that integrate efficient RNA encapsulation, site-specific delivery, and controlled RNA release, providing more tools and choices for RNA delivery.In this Account, we summarize recent advances from our group in the design and synthesis of LPHNPs for RNA therapeutics, as well as their translational applications across diverse disease contexts. We highlight rational material pairings and design principles that optimize key performance metrics, including colloidal stability, RNA loading, cellular uptake, endosomal escape, and targeting efficacy. We also provide case studies demonstrating the translational potential of RNA-LPHNPs across various administration routes and disease models, including oral, inhaled, intravenous, and intravesical delivery, using the LPHNP platforms developed in our laboratory. These platforms have achieved promising therapeutic efficacy in models of cancers, inflammatory diseases, and respiratory conditions by enabling local or systemic delivery of mRNA or siRNA to immune cells, epithelial cells, and tumor microenvironments. By outlining optimized design strategies and future challenges, this Account aims to serve as a roadmap for researchers seeking to develop next-generation RNA delivery platforms that are modular, functionally versatile, and translatable.
- 16 February 2026
- Published by American Chemical Society (ACS) in Accounts of Chemical Research
- Vol. 59 (5) , 762-775
Lipid–Polymer Hybrid Nanoparticles (LPHNPs) for RNA Delivery
ConspectusRNA-based therapeutics are now revolutionizing modern medicine, with examples like COVID-19 mRNA vaccines and the siRNA drug Leqvio, validating their potential in infectious diseases and chronic diseases. However, the broad clinical translation of RNA therapeutics remains critically dependent on the development of safe and effective delivery systems that are capable of overcoming physiological barriers and achieving precise spatiotemporal upregulation or downregulation of target proteins. Lipid nanoparticles (LNPs) have attracted significant attention due to their clinical success, yet they still struggle to overcome context-specific delivery barriers, such as poor stability in blood or gastrointestinal fluids, lack of disease-microenvironment responsiveness, and insufficient cell-type targeting, which hinder the full implementation of RNA therapeutics across a broad spectrum of diseases. To tackle the unmet needs in RNA-based therapeutics, developing new types of delivery platforms with different nanoparticle structures is therefore highly attractive and needed.Over the past decade, our group has focused on developing novel lipid-polymer hybrid nanoparticles (LPHNPs) for the delivery of RNA therapeutics across diverse biomedical applications. By incorporating biodegradable polymers with tailored properties, for example, poly(lactic-co-glycolic acid) (PLGA) for structural stability, hyaluronic acid (HA) for CD44-mediated targeted delivery, and l-cysteine-based poly(disulfide amide) (Cys-PDSA) for redox-responsive release in the tumor microenvironment, these LPHNPs exhibit highly tunable architectures that integrate efficient RNA encapsulation, site-specific delivery, and controlled RNA release, providing more tools and choices for RNA delivery.In this Account, we summarize recent advances from our group in the design and synthesis of LPHNPs for RNA therapeutics, as well as their translational applications across diverse disease contexts. We highlight rational material pairings and design principles that optimize key performance metrics, including colloidal stability, RNA loading, cellular uptake, endosomal escape, and targeting efficacy. We also provide case studies demonstrating the translational potential of RNA-LPHNPs across various administration routes and disease models, including oral, inhaled, intravenous, and intravesical delivery, using the LPHNP platforms developed in our laboratory. These platforms have achieved promising therapeutic efficacy in models of cancers, inflammatory diseases, and respiratory conditions by enabling local or systemic delivery of mRNA or siRNA to immune cells, epithelial cells, and tumor microenvironments. By outlining optimized design strategies and future challenges, this Account aims to serve as a roadmap for researchers seeking to develop next-generation RNA delivery platforms that are modular, functionally versatile, and translatable.
- Top Cited Papers
- 21 August 2025
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 125 (18) , 8835-8920
Therapeutic Hydrogels: Properties and Biomedical Applications
Hydrogels have emerged as versatile therapeutic platforms with immense potential for treating various diseases, due to their tunable properties and biocompatibility. Recent innovations, including injectable, self-assembling, and bioadhesive hydrogels, have broadened their biomedical applications, driven by advancements in materials chemistry. This review systematically examines the role of chemical principles in designing and customizing therapeutic hydrogels, with a focus on hydrogelation mechanisms, swelling ratios, mechanical properties, and biological interactions. By highlighting key studies in this field, this review explores how chemical chain modifications, cross-linking strategies, and cargo delivery systems have been tailored to achieve diverse functions, such as drug depots, wound dressings, antiadhesive barriers, and regenerative scaffolds. Addressing the gap in comprehensive analyses, this review underscores the integration of chemical design principles to optimize hydrogel properties for targeted therapies and discusses future opportunities to advance therapeutic hydrogel technology for a wide range of biomedical applications.
- 21 August 2025
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 125 (18) , 8835-8920
Top Cited PapersTherapeutic Hydrogels: Properties and Biomedical Applications
Hydrogels have emerged as versatile therapeutic platforms with immense potential for treating various diseases, due to their tunable properties and biocompatibility. Recent innovations, including injectable, self-assembling, and bioadhesive hydrogels, have broadened their biomedical applications, driven by advancements in materials chemistry. This review systematically examines the role of chemical principles in designing and customizing therapeutic hydrogels, with a focus on hydrogelation mechanisms, swelling ratios, mechanical properties, and biological interactions. By highlighting key studies in this field, this review explores how chemical chain modifications, cross-linking strategies, and cargo delivery systems have been tailored to achieve diverse functions, such as drug depots, wound dressings, antiadhesive barriers, and regenerative scaffolds. Addressing the gap in comprehensive analyses, this review underscores the integration of chemical design principles to optimize hydrogel properties for targeted therapies and discusses future opportunities to advance therapeutic hydrogel technology for a wide range of biomedical applications.
- Open Access
- 11 March 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (11)
Dual mRNA nanoparticles strategy for enhanced pancreatic cancer treatment and β-elemene combination therapy
Pancreatic ductal adenocarcinoma (PDAC) is notoriously immune-resistant, limiting the clinical efficacy of single-agent immune modulators and thereby necessitating the exploration of multimodal immunotherapy combinations. Traditional approaches combining conventional immune checkpoint inhibitors with neoantigen vaccines have shown some promise in treating PDAC but are often compromised by intratumoral T lymphocyte exhaustion and systemic toxicity. Hence, novel approaches are needed to address these challenges. Herein, we demonstrate that mRNA polymeric nanoparticles encoding anti-PD-1 antibodies in situ at the tumor site enhance the therapeutic efficacy of neoantigen-based mRNA vaccine for PDAC. This mRNA-based, in situ anti-PD-1 antibody production strategy also protects tumor-infiltrating T cells from PD-1 inhibition, potentially reducing the toxicities induced by systemic checkpoint inhibition. Our study may provide an innovative dual mRNA nanoparticle strategy for effective tumor neoantigen immunotherapy, as well as an mRNA cancer combination therapy strategy with other clinically approved drugs (e.g., β-elemene).
- 11 March 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (11)
Open AccessDual mRNA nanoparticles strategy for enhanced pancreatic cancer treatment and β-elemene combination therapy
Pancreatic ductal adenocarcinoma (PDAC) is notoriously immune-resistant, limiting the clinical efficacy of single-agent immune modulators and thereby necessitating the exploration of multimodal immunotherapy combinations. Traditional approaches combining conventional immune checkpoint inhibitors with neoantigen vaccines have shown some promise in treating PDAC but are often compromised by intratumoral T lymphocyte exhaustion and systemic toxicity. Hence, novel approaches are needed to address these challenges. Herein, we demonstrate that mRNA polymeric nanoparticles encoding anti-PD-1 antibodies in situ at the tumor site enhance the therapeutic efficacy of neoantigen-based mRNA vaccine for PDAC. This mRNA-based, in situ anti-PD-1 antibody production strategy also protects tumor-infiltrating T cells from PD-1 inhibition, potentially reducing the toxicities induced by systemic checkpoint inhibition. Our study may provide an innovative dual mRNA nanoparticle strategy for effective tumor neoantigen immunotherapy, as well as an mRNA cancer combination therapy strategy with other clinically approved drugs (e.g., β-elemene).
- 3 December 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (51) , 35252-35263
Elemene Hydrogel Modulates the Tumor Immune Microenvironment for Enhanced Treatment of Postoperative Cancer Recurrence and Metastases
As a representative active ingredient of traditional Chinese medicine (TCM) and a clinically approved anticancer drug, elemene (ELE) exhibits exciting potential in the antitumor field; however, appropriate drug formulations still need to be explored for specific diseases such as postoperative cancer recurrence and metastasis. Herein, we report an ELE hydrogel with controlled drug release kinetics that can allow ELE to maintain effective concentrations at local lesion sites for extended periods to enhance the bioavailability of ELE. Concretely, dopamine-conjugated hyaluronic acid is synthesized and utilized to prepare ELE nanodrug-embedded hydrogels. In a model of postoperative breast cancer recurrence and metastasis, the ELE hydrogel demonstrates a 96% inhibition rate of recurrence; in contrast, the free ELE nanodrug shows only a 65.5% inhibition rate of recurrence. Importantly, the ELE hydrogel markedly stimulates a potent antitumor immune response in the microenvironment of cancer lesions, increasing antitumor immune cells such as CD8+ T cells, CD4+ T cells, and M1-type macrophages, as well as elevating antitumor cytokines including TNF-α, IFN-γ, and IL-6. Overall, this study not only advances the field of TCM but also highlights the transformative impact of controlled-release hydrogels in improving antitumor therapy.
- 3 December 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (51) , 35252-35263
Elemene Hydrogel Modulates the Tumor Immune Microenvironment for Enhanced Treatment of Postoperative Cancer Recurrence and Metastases
As a representative active ingredient of traditional Chinese medicine (TCM) and a clinically approved anticancer drug, elemene (ELE) exhibits exciting potential in the antitumor field; however, appropriate drug formulations still need to be explored for specific diseases such as postoperative cancer recurrence and metastasis. Herein, we report an ELE hydrogel with controlled drug release kinetics that can allow ELE to maintain effective concentrations at local lesion sites for extended periods to enhance the bioavailability of ELE. Concretely, dopamine-conjugated hyaluronic acid is synthesized and utilized to prepare ELE nanodrug-embedded hydrogels. In a model of postoperative breast cancer recurrence and metastasis, the ELE hydrogel demonstrates a 96% inhibition rate of recurrence; in contrast, the free ELE nanodrug shows only a 65.5% inhibition rate of recurrence. Importantly, the ELE hydrogel markedly stimulates a potent antitumor immune response in the microenvironment of cancer lesions, increasing antitumor immune cells such as CD8+ T cells, CD4+ T cells, and M1-type macrophages, as well as elevating antitumor cytokines including TNF-α, IFN-γ, and IL-6. Overall, this study not only advances the field of TCM but also highlights the transformative impact of controlled-release hydrogels in improving antitumor therapy.
- 11 October 2024
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 24 (43) , 13825-13833
One-Pot Synthesis of Fe-Norepinephrine Nanoparticles for Synergetic Thermal-Enhanced Chemodynamic Therapy
Chemodynamic therapy (CDT) is an innovative and burgeoning strategy that utilizes Fenton-Fenton-like chemistry and specific microenvironments to produce highly toxic hydroxyl radicals (•OH), with numerous methods emerging to refine this approach. Herein, we report a coordination compound, Fe-norepinephrine nanoparticles (Fe-NE NPs), via a one-pot synthesis. The Fe-NE NPs are based on ferrous ions (Fe2+) and norepinephrine, which are capable of efficient Fe2+/Fe3+ delivery. Once internalized by tumor cells, the released Fe2+/Fe3+ exerts the Fenton reaction to specifically produce toxic •OH. Moreover, the internal photothermal conversion ability of Fe-NE NPs allows us to simultaneously introduce light to trigger local heat generation and then largely improve the Fenton reaction efficiency, which enables a synergetic photothermal and chemodynamic therapy to realize satisfactory in vivo antitumor efficiency. This proof-of-concept work offers a promising approach to developing nanomaterials and refining strategies for enhanced CDT against tumors.
- 11 October 2024
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 24 (43) , 13825-13833
One-Pot Synthesis of Fe-Norepinephrine Nanoparticles for Synergetic Thermal-Enhanced Chemodynamic Therapy
Chemodynamic therapy (CDT) is an innovative and burgeoning strategy that utilizes Fenton-Fenton-like chemistry and specific microenvironments to produce highly toxic hydroxyl radicals (•OH), with numerous methods emerging to refine this approach. Herein, we report a coordination compound, Fe-norepinephrine nanoparticles (Fe-NE NPs), via a one-pot synthesis. The Fe-NE NPs are based on ferrous ions (Fe2+) and norepinephrine, which are capable of efficient Fe2+/Fe3+ delivery. Once internalized by tumor cells, the released Fe2+/Fe3+ exerts the Fenton reaction to specifically produce toxic •OH. Moreover, the internal photothermal conversion ability of Fe-NE NPs allows us to simultaneously introduce light to trigger local heat generation and then largely improve the Fenton reaction efficiency, which enables a synergetic photothermal and chemodynamic therapy to realize satisfactory in vivo antitumor efficiency. This proof-of-concept work offers a promising approach to developing nanomaterials and refining strategies for enhanced CDT against tumors.
Inflammation Self‐Limiting Electrospun Fibrous Tape via Regional Immunity for Deep Soft Tissue Repair
Overexpression of inflammatory cytokines and chemokines occurs at deep soft tissue injury sites impeding the inflammation self‐limiting and impairing the tissue remodeling process. Inspired by the electrostatically extracellular matrix (ECM) binding property of the inflammatory signals, an inflammation self‐limiting fibrous tape is designed by covalently modifying the thermosensitive methacrylated gelatin (GelMA) and negatively charged methacrylated heparin (HepMA) hydrogel mixture with proper ratio onto the electrospun fibrous membrane by mild alkali hydrolysis and carboxyl‐amino condensation reaction to restore inflammation self‐limiting and promote tissue repair via regional immunity regulation. While the GelMA guarantees cell compatibility, the negatively charged HepMA successfully adsorbs the inflammatory cytokines and chemokines by electrostatic interactions and inhibits immune cell migration in vitro. Furthermore, in vivo inflammation self‐limiting and regional immunity regulation efficacy is evaluated in a rat abdominal hernia model. Reduced local inflammatory cytokines and chemokines in the early stage and increased angiogenesis and ECM remodeling in the later phase confirm that the tape is an approach to maintain an optimal regional immune activation level after soft tissue injury. Overall, the reported electrospun fibrous tape will find its way into clinical transformation and solve the challenges of deep soft tissue injury.
Inflammation Self‐Limiting Electrospun Fibrous Tape via Regional Immunity for Deep Soft Tissue Repair
Overexpression of inflammatory cytokines and chemokines occurs at deep soft tissue injury sites impeding the inflammation self‐limiting and impairing the tissue remodeling process. Inspired by the electrostatically extracellular matrix (ECM) binding property of the inflammatory signals, an inflammation self‐limiting fibrous tape is designed by covalently modifying the thermosensitive methacrylated gelatin (GelMA) and negatively charged methacrylated heparin (HepMA) hydrogel mixture with proper ratio onto the electrospun fibrous membrane by mild alkali hydrolysis and carboxyl‐amino condensation reaction to restore inflammation self‐limiting and promote tissue repair via regional immunity regulation. While the GelMA guarantees cell compatibility, the negatively charged HepMA successfully adsorbs the inflammatory cytokines and chemokines by electrostatic interactions and inhibits immune cell migration in vitro. Furthermore, in vivo inflammation self‐limiting and regional immunity regulation efficacy is evaluated in a rat abdominal hernia model. Reduced local inflammatory cytokines and chemokines in the early stage and increased angiogenesis and ECM remodeling in the later phase confirm that the tape is an approach to maintain an optimal regional immune activation level after soft tissue injury. Overall, the reported electrospun fibrous tape will find its way into clinical transformation and solve the challenges of deep soft tissue injury.
- Open Access
- 6 July 2022
- Published by Elsevier in The Innovation
- Vol. 3 (5) , 100282
From “organs on a chip” to “patient on a chip”
- 6 July 2022
- Published by Elsevier in The Innovation
- Vol. 3 (5) , 100282
Open AccessFrom “organs on a chip” to “patient on a chip”
- 5 January 2022
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (10) , 2102534
Regulated Exogenous/Endogenous Inflammation via “Inner‐Outer” Medicated Electrospun Fibers for Promoting Tissue Reconstruction
Regenerative medicine aims to provide solutions for structural and functional recovery in conditions where organs suffer from varying degrees of diseases or injuries. However, the exogenous inflammation triggered by implanted biomaterials and endogenous inflammation caused by some disease or tissue destruction has not been solved properly yet. Herein, a functional “inner‐outer” medicated core–shell electrospun fibrous membrane is fabricated with RGD surface modification for exogenous inflammation suppression and puerarin loading in the core for long‐term endogenous inflammation inhibition through microsol electrospinning technique. The “outer” RGD significantly increases biocompatibility of fibrous membrane through promoting cell viability, adhesion, and proliferation while the “inner” puerarin suppresses inflammatory gene expression via sustained drug release in vitro. Moreover, in a rat abdominal wall hernia model, the functional fibrous membrane successfully reduces exogenous and endogenous inflammation response and promotes wound healing through collagen deposition, smooth muscle formation, and vascularization. In summary, the functional “inner‐outer” medicated fibrous membrane holds a great potential for clinical treatment of diseases that needs tissue reconstruction structurally and functionally accompanied by immunoregulation.
- 5 January 2022
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (10) , 2102534
Regulated Exogenous/Endogenous Inflammation via “Inner‐Outer” Medicated Electrospun Fibers for Promoting Tissue Reconstruction
Regenerative medicine aims to provide solutions for structural and functional recovery in conditions where organs suffer from varying degrees of diseases or injuries. However, the exogenous inflammation triggered by implanted biomaterials and endogenous inflammation caused by some disease or tissue destruction has not been solved properly yet. Herein, a functional “inner‐outer” medicated core–shell electrospun fibrous membrane is fabricated with RGD surface modification for exogenous inflammation suppression and puerarin loading in the core for long‐term endogenous inflammation inhibition through microsol electrospinning technique. The “outer” RGD significantly increases biocompatibility of fibrous membrane through promoting cell viability, adhesion, and proliferation while the “inner” puerarin suppresses inflammatory gene expression via sustained drug release in vitro. Moreover, in a rat abdominal wall hernia model, the functional fibrous membrane successfully reduces exogenous and endogenous inflammation response and promotes wound healing through collagen deposition, smooth muscle formation, and vascularization. In summary, the functional “inner‐outer” medicated fibrous membrane holds a great potential for clinical treatment of diseases that needs tissue reconstruction structurally and functionally accompanied by immunoregulation.